Arnaldos-Carrillo, MaríaNoguera-Velasco, José AntonioMartínez-Ardil, Isabel MRiquelme-Pérez, AlejandroCebreiros-López, IriaHernández-Vicente, ÁlvaroRos-Lucas, José AntonioKhan, AmjadBayes-Genís, AntoniPascual-Figal, Domingo A2024-05-102024-05-102023-09-08Med Clin (Barc). 2023 Sep 8;161(5):185-191.http://hdl.handle.net/20.500.12105/19358BACKGROUND Soluble suppressor of tumorigenicity-2 (sST2) is a biomarker for heart failure and pulmonary injury. We hypothesize that sST2 could help predict severity of SARS-CoV-2 infections. METHODS sST2 was analyzed in patients consecutively admitted for SARS-CoV-2 pneumonia. Other prognostic markers were also measured. In-hospital complications were registered, including death, ICU admission, and respiratory support requirements. RESULTS 495 patients were studied (53% male, age: 57.6±17.6). At admission, median sST2 concentrations was 48.5ng/mL [IQR, 30.6-83.1ng/mL] and correlated with male gender, older age, comorbidities, other severity biomarkers, and respiratory support requirements. sST2 levels were higher in patients who died (n=45, 9.1%) (45.6 [28.0, 75.9]ng/mL vs. 144 [82.6, 319] ng/mL, p<0.001) and those admitted to ICU (n=46, 9.3%) (44.7 [27.5, 71.3] ng/mL vs. 125 [69.0, 262]ng/mL, p<0.001). sST2 levels>210ng/mL were a strong predictor of complicated in-hospital courses, with higher risk of death (OR, 39.3, CI95% 15.9, 103) and death/ICU (OR 38.3, CI95% 16.3-97.5) after adjusting for all other risk factors. The addition of sST2 enhanced the predictive capacity of mortality risk models. CONCLUSIONS sST2 represents a robust severity predictor in COVID-19 and could be an important tool for identifying at-risk patients who may benefit from closer follow-up and specific therapies.engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/Interleukin-1 Receptor-Like 1 ProteinCOVID-19HumansMaleAdultMiddle AgedAgedFemalePrognosisSARS-CoV-2BiomarkersAttribution-NonCommercial-NoDerivatives 4.0 InternacionalAttribution-NonCommercial-NoDerivatives 4.0 Internacional37137804161518510.1016/j.medcli.2023.04.0051578-8989Medicina clinicaopen access